Chromosome 12p Deletion malady

Categories: Rare diseases

Aliases & Classifications for Chromosome 12p Deletion

Aliases & Descriptions for Chromosome 12p Deletion:

Name: Chromosome 12p Deletion 50 29
Loss of Chromosome 12p 69
Partial Monosomy 12p 50
12p Deletion 50
12p Monosomy 50
Deletion 12p 50
Monosomy 12p 50


Summaries for Chromosome 12p Deletion

MalaCards based summary : Chromosome 12p Deletion, also known as loss of chromosome 12p, is related to distal monosomy 12p and multiple myeloma. The drugs Ethanol and Histamine have been mentioned in the context of this disorder.

Related Diseases for Chromosome 12p Deletion

Diseases related to Chromosome 12p Deletion via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 distal monosomy 12p 10.9
2 multiple myeloma 9.8
3 acute lymphocytic leukemia 9.8
4 leukemia 9.8

Symptoms & Phenotypes for Chromosome 12p Deletion

Drugs & Therapeutics for Chromosome 12p Deletion

Drugs for Chromosome 12p Deletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Ethanol Approved Phase 4 64-17-5 702
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
Sodium oxybate Approved Phase 4 502-85-2 5360545
Oxazepam Approved Phase 4 604-75-1 4616
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Butyric Acid Experimental Phase 4 107-92-6 264
7 vitamin d Phase 4
Histamine Phosphate Phase 4 51-74-1 65513
9 Adjuvants, Anesthesia Phase 4
10 GABA Agents Phase 4
11 GABA Modulators Phase 4
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Histamine Antagonists Phase 4
14 Trace Elements Phase 4
15 Tranquilizing Agents Phase 4
16 Anesthetics Phase 4
17 Vaccines Phase 4
18 Anesthetics, General Phase 4
19 Anesthetics, Intravenous Phase 4
20 Ergocalciferols Phase 4
21 Anti-Anxiety Agents Phase 4
22 Hypnotics and Sedatives Phase 4
23 Vitamins Phase 4
24 Povidone Phase 4
25 Anti-Infective Agents Phase 4,Phase 2
26 Anti-Infective Agents, Local Phase 4
27 Psychotropic Drugs Phase 4
28 Micronutrients Phase 4
29 Bone Density Conservation Agents Phase 4
30 Central Nervous System Depressants Phase 4
31 Vitamin D2 Nutraceutical Phase 4
32 Calciferol Nutraceutical Phase 4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
Idarubicin Approved Phase 3 58957-92-9 42890
Pancrelipase Approved Phase 3,Phase 2 53608-75-6
Salmeterol xinafoate Phase 3 94749-08-3 56801
37 Adrenergic Agents Phase 3
38 Formoterol Fumarate Phase 3
39 Adrenergic Agonists Phase 3
40 Adrenergic beta-2 Receptor Agonists Phase 3
41 Adrenergic beta-Agonists Phase 3
42 Topoisomerase Inhibitors Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 3,Phase 2
44 Pharmaceutical Solutions Phase 3,Phase 2
45 Anti-Asthmatic Agents Phase 3
46 Anti-Bacterial Agents Phase 3,Phase 2
47 Etoposide phosphate Phase 3,Phase 2
48 Respiratory System Agents Phase 3,Phase 2
49 Antibiotics, Antitubercular Phase 3,Phase 2
50 Autonomic Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 40)
id Name Status NCT ID Phase
1 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4
2 Bioequivalence of Ethylenediamine Dihydrochloride Study Completed NCT01798589 Phase 4
3 The Safety and Immune Response to Influenza Vaccination in Pregnant Women Completed NCT01514708 Phase 4
4 Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients Completed NCT00294866 Phase 4
5 Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result Completed NCT00146120 Phase 3
6 Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD Completed NCT00064402 Phase 3
7 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Recruiting NCT02514928 Phase 3
8 Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response Terminated NCT00159926 Phase 3
9 A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease Completed NCT00265122 Phase 2
10 A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis Completed NCT00207727 Phase 2
11 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2
12 A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Completed NCT01135511 Phase 2
13 Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning Recruiting NCT02952716 Phase 1, Phase 2
14 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Suspended NCT01979536 Phase 2
15 Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer Terminated NCT01116791 Phase 2
16 Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects Completed NCT02211170 Phase 1
17 A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors Recruiting NCT02627274 Phase 1
18 A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531 Recruiting NCT02956850 Phase 1
19 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Active, not recruiting NCT01703507 Phase 1
20 Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies Unknown status NCT00837278
21 Genetic Disease Gene Identification Unknown status NCT00916903
22 Exercise-induced Bronchoconstriction in School Children Unknown status NCT01798823
23 Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma Completed NCT00323206
24 Keratinocyte Growth Factor and Cytokines in Burns. Completed NCT01302223
25 Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder Completed NCT01862653
26 0.2 ml vs. 0.5 Inseminated Volume in Donor Intrauterine Insemination Cycles: A Prospective RCT Completed NCT03006523
27 Low Dose Naltrexone (LDN) Immune Monitoring Completed NCT02107014
28 Post-bypass Prophylactic IVIG in Infants and Neonates Completed NCT02043379
29 Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition Completed NCT02743195
30 Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended? Recruiting NCT02787187
31 Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduodenectomy Recruiting NCT03081351
32 Bioavailability and Beneficial Properties of Coffee and Cocoa Bioactive Compounds Recruiting NCT03166540
33 Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder Recruiting NCT02992899
34 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma Active, not recruiting NCT02097134
35 (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil? Active, not recruiting NCT02310789 Early Phase 1
36 Airway Inflammatory Response During Illness in Children With Respiratory Failure Not yet recruiting NCT02047877
37 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Suspended NCT01798004
38 Reiki for the Management of Neuropathic Pain Terminated NCT02328703
39 Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat") Terminated NCT00764179
40 Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery Withdrawn NCT02671552

Search NIH Clinical Center for Chromosome 12p Deletion

Genetic Tests for Chromosome 12p Deletion

Genetic tests related to Chromosome 12p Deletion:

id Genetic test Affiliating Genes
1 Chromosome 12p Deletion 29

Anatomical Context for Chromosome 12p Deletion

Publications for Chromosome 12p Deletion

Articles related to Chromosome 12p Deletion:

id Title Authors Year
Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. ( 25831238 )
Analysis of chromosome 12p deletion in plasma cell dyscrasias. ( 21982640 )
ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. ( 9305598 )

Variations for Chromosome 12p Deletion

Expression for Chromosome 12p Deletion

Search GEO for disease gene expression data for Chromosome 12p Deletion.

Pathways for Chromosome 12p Deletion

GO Terms for Chromosome 12p Deletion

Sources for Chromosome 12p Deletion

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....